论文部分内容阅读
目的管理和观察儿童艾滋病抗病毒治疗过程,为儿童艾滋病规范治疗和管理提供依据。方法对符合条件的儿童艾滋病病人提供高效抗逆转录病毒治疗(HAART)并定期进行临床随访观察和相关实验室检测。结果40例儿童艾滋病病人HAART治疗9个月之前的依从性均能达到95%。儿童的生长发育指标—身高、体重在抗病毒治疗第6个月时均大于第3个月时(P<0.05);3个月和6个月时均大于基线时(P<0.05)。临床症状除持续或间断1个月发热(治疗6个月时)发生5例(17.9%),其他症状发生率均小于10%;除艾滋病脑病1例(5%)以外,没有发生新的严重机会性感染。免疫学指标—CD4+T淋巴细胞计数由基线均值103.73±103.89个/u l上升到治疗12个月时的536.60±344.63个/u l(F=8.137,P<0.05);平均每治疗3个月CD4T淋巴细胞计数上升约100左右。病毒学指标—病毒载量水平在治疗6个月以上时,病毒复制抑制(VL<10 000 Cop ies/m l)达到50%~80%。结论我省儿童抗病毒治疗具有良好的依从性,治疗效果明显,反映在儿童生长发育指标、临床指标、免疫学指标、病毒学指标等方面。
Objective To manage and observe the course of AIDS virus treatment in children and provide the basis for the standard treatment and management of AIDS in children. Methods Eligible AIDS patients were provided with high-efficiency antiretroviral therapy (HAART) and regular clinical follow-up observation and related laboratory tests. Results 40 cases of AIDS patients HAART treatment compliance nine months ago can reach 95%. Children’s growth and development indicators - height and weight at 6 months after antiviral therapy were greater than the 3rd month (P <0.05); 3 months and 6 months were significantly greater than the baseline (P <0.05). Clinical symptoms occurred in 5 cases (17.9%) with sustained or intermittent 1-month fever (6 months), and other symptoms were less than 10%; except for 1 case of AIDS encephalopathy (5%), no new serious Opportunistic infection. Immunological indicators-CD4 + T lymphocyte count increased from baseline 103.73 ± 103.89 / ul to 536.60 ± 344.63 / ul (F = 8.137, P <0.05) at 12 months of treatment; with an average of 3 months for each treatment Lymphocyte count rose about 100 or so. Virological Indicators - Viral Replication Inhibition (VL <10 000 Copies / m l) reaches 50% to 80% at 6 months of therapy. Conclusion The treatment of children with antiviral therapy in our province has good compliance and the therapeutic effect is obvious, which is reflected in the indicators of child growth and development, clinical indicators, immunological indicators, virological indicators and so on.